Paper Review Records
全部论文审稿周期
5 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
143
天
PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study
作者
Anna Passarelli; Giovanni Luca Scaglione; Daniela Califano; Michele Bartoletti; Domenica Lorusso; Sabrina Chiara Cecere; Anna Fagotti; Alberto Farolfi; Claudia Andreetta; Jole Ventriglia; Laura Arenare; Carmela Pisano; Daniela Russo; Maria Teresa Perri; Saverio Cinieri; Simona Scalone; Ugo De Giorgi; Valentina Arcangeli; Elena Zafarana; Maria Chiara Cannizzaro; Serafina Mammoliti; Tommaso Ambrosio; Rossella De Cecio; Clorinda Schettino; Francesco Perrone; Sandro Pignata展开收起
作者单位
1. Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori—IRCCS—Fondazione G. Pascale, Naples, Italy; 2. Bioinformatics Unit, Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy; 3. Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori—IRCCS—Fondazione G. Pascale, Naples, Italy; 4. Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy; 5. Division of Gynecologic Oncology, Humanitas San Pio X, Milan, Italy; 6. Department of Biomedical Sciences, Humanitas University, Milan, Italy; 7. Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; 8. Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy; 9. Department of Medical Oncology, “S. Maria della Misericordia” University Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; 10. Clinical Trial Unit, Istituto Nazionale Tumori—IRCCS—Fondazione G. Pascale, Naples, Italy; 11. U.O.C. Oncologia Medica-Ospedale Senatore Antonio Perrino, Brindisi, Italy; 12. Department of Experimental Medicine, University of Salento, Fazzi Hospital, Lecce, Italy; 13. Romagna Cancer Registry IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola, Italy; 14. Department of Oncology, Hospital of Prato Azienda USL Toscana Centro, Prato, Italy; 15. AOM Liguria, Azienda Ospedaliera Metropolitana di Genova, Genoa, Italy; 16. Division of Anatomic Pathology and Cytopathology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, Italy展开收起
184
天
Tailoring Escalated Adjuvant Chemotherapy for Multifocal and Multicentric Breast Cancer With Low Tumor Burden
作者
Yonghui Su; Jiaqi Ying; Zhuozhao Zhan; Tingting Wu; Yena Yu; Wanxin Gao; Yizi Zheng展开收起
作者单位
1. Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China; 2. Department of Breast Surgery, Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China; 3. Department of Mathematics and Computer Science, Eindhoven University of Technology, Eindhoven, the Netherlands展开收起
84
天
Decoding Treatment Response and Prognosis in Unresectable Locally Advanced Non–Small Cell Lung Cancer by Integrating Spatiotemporal Heterogeneity From 18F-FDG Positron Emission Tomography-Computed Tomography: A Multicenter Study
作者
Yu Ji; Jiaqi Wang; Meixia Zhou; Yaru Wang; Zhengjun Dai; Jingsong Zheng展开收起
作者单位
1. Department of Radiology, The Second Qilu Hospital of Shandong University, Jinan, Shandong, China; 2. Department of Cancer Medical Center, People's Hospital of Chengwu County, Heze, Shandong, China; 3. Department of Radiology, Shandong University, Jinan, Shandong, China; 4. Institute of Research and Clinical Innovations, Neusoft Medical Systems Co. Ltd, Beijing, China; 5. Center for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China展开收起
133
天
Tumor-Free Circulating Tumor DNA in Node-Negative Rectal Cancers Undergoing Neoadjuvant Chemotherapy, Excision, and Observation in the Phase II NEO Trial (CO.28)
作者
Jonathan M. Loree; Emma Titmuss; Carl J. Brown; Thereasa Rich; Kimberly Banks; Vallerie Gordon; Sunil Patel; Marianne Krahn; Antonio Caycedo-Marulanda; Manoj Raval; Dongsheng Tu; Derek J. Jonker; Christopher J. O'Callaghan; Hagen F. Kennecke展开收起
作者单位
1. BC Cancer, Vancouver, BC, Canada; 2. Canadian Cancer Trials Group, Kingston, ON, Canada; 3. St Paul's Hospital, Vancouver, BC, Canada; 4. Guardant Health, Palo Alto, CA; 5. Saskatchewan Cancer Agency, Saskatoon, SK, Canada; 6. Kingston Health Sciences Centre, Kingston, ON, Canada; 7. Cancer Care Manitoba, Winnipeg, MB, Canada; 8. Northern Ontario School of Medicine, Sudbury, ON, Canada; 9. The Ottawa Hospital, Ottawa, ON, Canada; 10. Oregon Health Sciences Institute, Portland, OR展开收起
87
天
Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAFV600E- or BRAFInsT-Mutant Brain Tumors: PNOC002
作者
Theodore Nicolaides; Raoull Hoogendijk; Marie Jaeger-Krause; Girish Dhall; Stewart Goldman; Amar Gajjar; Lindsay Kilburn; Sarah Leary; Jane Minturn; Nicholas Whipple; Divya Ramakrishnan; Janel Long-Boyle; Mariam Aboian; Michael Prados; Annette M. Molinaro; Sabine Mueller展开收起
作者单位
1. Caris Life Sciences, Irving, TX; 2. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; 3. Department of Neurology, Brain Tumor Center, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands; 4. Department of Pediatrics, University of California, San Francisco, San Francisco, CA; 5. Division of Hematology & Oncology, University of Alabama, Birmingham, AL; 6. Phoenix Children's Hospital, University of Arizona College of Medicine, Phoenix, AZ; 7. St Jude Children's Research Hospital, Memphis, TN; 8. Center for Cancer and Blood Disorders, Brain Tumor Institute, Children's National Health System, Washington, DC; 9. Seattle Children's Hospital, Seattle, WA; 10. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 11. University of Utah, Salt Lake City, UT; 12. Department of Radiology, Stanford University School of Medicine, Stanford, CA; 13. Department of Clinical Pharmacy, University of California San Francisco (UCSF) School of Pharmacy, San Francisco, CA; 14. Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA; 15. Department of Neurology, University of California, San Francisco, San Francisco, CA; 16. University Children's Hospital Zurich, Zurich, Switzerland展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天